BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Horizon Medical Services

  BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Horizon
  Medical Services

Business Wire

SALT LAKE CITY -- January 7, 2013

BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today
that Horizon Medical Services (Horizon) in Tamarac, Florida has purchased a
BSD-500 Hyperthermia System (BSD-500). Horizon is a sophisticated,
freestanding, mobile radiation therapy center that offers technologically
advanced cancer care in the South Florida area. Horizon has offices in Miami
and in Coral Springs. Horizon's mobile radiation therapy units provide
treatments throughout Southern Florida. The purchase of the BSD-500 by Horizon
increases the number of patients who will have access to innovative
hyperthermia treatment. This sale is further evidence of the growing use of
hyperthermia therapy in Florida and in the United States.

“Clinical studies have shown that hyperthermia delivered using the BSD-500 can
significantly increase the effectiveness of radiation therapy without a
significant increase in toxicity for certain tumors. We are excited to have a
BSD hyperthermia system placed in the prestigious Horizon Medical Services
facility,” stated Harold Wolcott, BSD's President.

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is used to deliver therapeutic heating
(hyperthermia) using either non-invasive (external) hyperthermia, which is
delivered using antennas placed over the tumor, or interstitial hyperthermia,
which is delivered using antennas that are inserted into the tumor, or a
combination of both. The BSD-500 has received U.S. Food and Drug
Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in
conjunction with radiation therapy to treat certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.